Inclusion Criteria:

- Patient is a male or female at least 18 years old

- Patient has relapsed or refractory MM and has had at least one prior therapy

- Female patients of childbearing potential must have 2 negative serum pregnancy tests
prior to receiving the first dose of study drugs

- Female patients who can become pregnant must agree to use 2 separate forms of
effective birth control at the same time, 4 weeks before, while taking, and for 4
weeks after stopping lenalidomide. Post menopausal patients should be free from
menses for > 2 years, or are surgically sterilized

- Male patient agrees to use an adequate method of contraception for the duration of
the study, even if the patient has undergone a successful vasectomy

- Male patients must agree to use a latex condom during sexual contact with a pregnant
female or a female who can become pregnant. This is required for the duration of the
study, and for 4 weeks after stopping therapy

- Patient has at least 3 weeks washout prior to treatment

- Patient is able to swallow capsules and is able to take or tolerate oral medications
on a continuous basis

Exclusion Criteria:

- Patient has prior treatment with an histone deacetylase (HDAC) inhibitor

- Patient has prior allogenetic bone marrow transplant

- Patient has received intravenous antibiotics, antiviral, or antifungal agents within
2 weeks prior to the start of the study drug

- Patient uses illicit drugs, substance abuse or had a recent history (within the last
year) of drug or alcohol abuse

- Patient is pregnant or breast feeding or expecting to have a baby during the course
of the study

- Patient has human immunodeficiency virus (HIV) infection

- Patient has Hepatitis B/C infection

- Patient is currently receiving treatment for another type of cancer other than skin
or cervical cancer that has not been in remission for 5 years or longer